LIM domain containing proteins play critical roles in animal development and cellular differentiation. Here, we describe the cloning and expression patterns of three members of the four and a half LIM domain-only protein family, FHL1, 2, and 3, from mouse. A comparison of embryonic expression patterns of these three highly-related genes indicates that they are expressed in an overlapping pattern in the developing cardiovascular system, and skeletal muscle. In adult tissues, the three genes are expressed in a predominant and overlapping manner in cardiac and skeletal muscle. Of the three genes, FHL2 appears to have the most restricted expression pattern during development, in heart, blood vessels, and skeletal muscle. Expression in heart is highest in cardiac septa and in the region adjacent to the atrio-ventricular ring, suggesting a potential role in septation or conduction system development. In the heart, FHL1expression was observed strongly in developing out¯ow tract, and to a lesser extent in myocardium. FHL3 displays low and ubiquitous expression during mouse development. Cardiac ventricular expression of FHL1, but not FHL2 or FHL3, was upregulated in two mouse models of cardiac hypertrophic and dilated cardiomyopathy. Taken together, these data indicate the potential importance of this FHL family in the development and maintenance of the cardiovascular system and striated muscle, and suggest that FHL1 may play a role in the development of heart disease. q
Results and discussion
LIM domains are protein-protein interaction domains that are receiving increasing attention from cellular and molecular biologists. Named after their initial discovery in two Caenorhabdits elegans gene products, lin-11 and mec-3, and the rat insulin enhancer binding protein, Islet-1 (Way and Chal®e, 1988; Freyd et al., 1990; Karlsson et al., 1990) , LIM domains have since been identi®ed in many proteins (Dawid et al., 1998) . The LIM domain is a cysteine rich motif having the consensus sequence CX 2 CX 16± 23 HX 2 CX 2 CX 2 CX 16±21 CX 2 (C, H, D) that coordinately binds two zinc atoms and mediates protein-protein interactions (Arber and Caroni, 1996) . Previous studies have revealed that some LIM domain containing proteins are nuclear proteins involved in cell lineage determination and pattern formation during development, whereas others encode cytosolic proteins associated with the cytoskeleton, and have been found to play a role in adhesion plaque and actin micro®lament organization (Zhou et al., 1980; Lumsden, 1995; Beckerle, 1997; Dawid et al., 1998) .
A newly identi®ed group of LIM-only proteins with four and half LIM domains (FHL) Lee et al., 1998) are enriched in striated muscle. This family consists of four members, three of which are expressed in adult striated muscle: FHL1/SLIM1, FHL2/SLIM3, and FHL3/ SLIM2 (SLIM is an acronym for skeletal muscle LIM, Morgan and Madgwick, 1996) . The fourth member of this family, FHL4 (accession number: AA144955), may be expressed exclusively in testes, as inferred from electronic Northern blot' analyses, utilizing the full-length FHL4 cDNA sequence to search the EST data base. This analysis revealed that matching sequences were found only in ESTs from testis cDNA libraries. In con®rmation of our search, a recent publication has also shown that FHL4 is expressed in testes (Morgan and Madgwick, 1999 ). An accumulating body of evidence indicates that FHL proteins may play important roles in both cardiac and striated muscle (Genini et al., 1997; Hwang et al., 1997; Takahashi et al., 1998 (Fig. 1) .
All FHL family members contain four and a half LIM domains and share high homology throughout their amino acid sequences. Lengths of the LIM1, LIM2, and LIM3 domains (53, 53, 51 amino acids, respectively) are similar among all FHL family members, as is the length of the half-LIM domain (25 amino acids). However, the length of the LIM4 domain varies among different FHL family members. LIM4 consists of 56 amino acids in both human and mouse FHL1, and 55 amino acids in human and mouse FHL2, and human FHL3. Interestingly, when compared to human FHL3, mouse FHL3 LIM4 has a 9 amino acid insertion resulting in a 64 amino acid domain.
To ensure that the 9 amino acid insertion in mouse FHL3 was not a cloning artifact, we performed reverse-transcription polymerase chain reaction (RT-PCR) analysis of adult heart RNA utilizing two primers¯anking the insertion. Gel electrophoresis revealed one PCR product and sequencing of the subcloned PCR product con®rmed the 9 amino acid insertion. The functional consequences of this insertion remain to be explored.
Results of Northern blot analyses (Fig. 2 ) demonstrated that FHL1 is expressed predominantly in skeletal muscle and lung, and to a lesser extent in heart, brain, and kidney. FHL2 is expressed strongly in heart, and also detectable in brain and skeletal muscle. FHL3 is highly expressed in skeletal muscle, and to a lesser extent in heart, lung, and kidney.
To exploit FHL1 and FHL2 as potential lineage markers, we performed homologous recombination to introduce a LacZ cDNA into the endogenous FHL1 and FHL2 loci (Chu and Chen, manuscript in preparation). Assays for b-galactosidase activity are very sensitive and give resolution at single cell level, permitting a detailed examination of FHL1 and FHL2 expression during embryogenesis. We have veri®ed that the pattern of expression obtained from the LacZ knock-in mice truly re¯ects expression of endogenous FHL1 and FHL2 by performing RNA in situ hybridization both by whole mount analysis with non-radioactive probes, and by analysis of sectioned embryos with radioactive probes. The wholemount RNA in situ with non-radioactive probes gives us a three-dimensional image of the expression pattern, whereas the radioactive RNA in situ with sections provides greater sensitivity. In addition, section analysis is required for later stages of embryonic development. We have also performed RNA in situ analysis of FHL3 to compare its expression to that of FHL1 and FHL2. Our analyses demonstrated that FHL1 mRNA could be detected at embryonic day (E)8.5, with high expression in the out¯ow tract (Fig. 3A) . At E10.5, FHL1 mRNA was observed in heart, somites, limb buds, neural tube, brain and eye (Fig. 3B,C) . At E14, strong expression of FHL1 was observed in neural tube and vasculature (aorta, pulmonary trunk) and lower levels of expression were observed in myocardium (Fig. 4A) . Strong hybridization signals for 1 RNA from adult mouse heart (H), brain (B), spleen (Sp), lung (Lu), liver (Li), skeletal muscle (Sk), kidney (K), and testis (T). Probes for each FHL mRNA were generated as detailed in Materials and Methods. An EF-1a cDNA probe was used to normalize for RNA loading. The position of RNA molecular weight standards (in kb) is indicated on the right. Fig. 3 . X-gal staining of FHL1 LacZ/knock-in mice during embryonic development. X-gal staining of FHL1 LacZ/knock-in mice revealed that FHL1 is expressed in the out¯ow tract (arrowheads) at the heart looping stage (E8.5) (A); and in the heart, somites, neural tubes and developing limb buds (B,C). (B) and (C) are lateral and dorsal views, respectively. Symbols are: FL, forelimb; H, heart; HL, hindlimb, NT, neural tubes; S, somites.
FHL1 at E14 were also observed in tongue (Fig. 4B) , Limb buds, abdominal muscle (Fig. 4C,D) , intercostal muscle, and thoracic muscle (Fig. 4D) .
Previous analysis performed by whole mount in situ with digoxygenin-labeled probes indicated that early embryonic expression of FHL1 is restricted to the out¯ow tract (Brown et al., 1999) . This result is consistent with our data obtained in the same manner. However, our data utilizing more sensitive detection techniques demonstrated that FHL1 is not only expressed in out¯ow tract but also at lower levels in embryonic myocardium (Fig. 3A,B) .
Of the three genes, FHL2 exhibited the most restricted expression pattern, being expressed predominantly in the cardiovascular system and in skeletal muscle. At E8.0± E8.5, FHL2 was expressed predominately in heart (Fig.  5A,B) . At E10, FHL2 was strikingly expressed in developing vasculature, including the aortic arch arteries, dorsal aorta, and intersegmental arteries (Fig. 5C ). At E14, FHL2 continued to be expressed in all compartments of the heart, with highest levels in the ventricular septum and at the junctional region of atria and ventricle (Fig. 6A,D) . FHL2 was also detected in other striated muscle (tongue) (Fig.  6B ), smooth muscle (midgut) (Fig. 6C) , vasculature (umbilical vein), and the area surrounding Rathke's pouch within the pituitary primordium (Fig. 6B) .
Our data represent the ®rst analysis of FHL2 expression in developing embryos. Interestingly, expression of FHL2 in embryonic heart is highest in the ventricular septum and areas adjacent to the atrio-ventricular ring (Fig. 6 ). This expression pattern suggests that FHL2 may play a role in the development and function of cardiac septa, and in the cardiac conduction system. The striking expression of FHL2 in the developing vasculature suggests that it also play an important role in the development of the circulatory system. Fig. 4 . Radioactive in situ hybridization analyses of FHL1 mRNA during embryonic development. At E14, FHL1 expression is enhanced in the ventricular out¯ow tract and great vessels (A); neural tube (B) (see arrowhead); limb and abdominal muscles (C); tongue and intercostal muscles (D). Symbols are: aa, aorta; ab-m, abdominal muscle; icm, intercostal muscles; lb, limb; lg, lung; nt, neural tube; pt, pulmonary trunk; sp, interventricular septum; tn, tongue; tr-m, thoracic muscle; v, ventricle. Fig. 5 . X-gal staining of FHL2 LacZ/knock-mice during early embryonic development. X-gal staining of FHL2 LacZ/knock-in mice revealed speci®c staining for heart and developing vasculature. The LacZ positive staining was observed in the fused heart tube at E8.0 (A); the looping heart at E8.5 (B); heart, dorsal aorta, and arteries at E10±10.5 (C). Symbols are: Ao, aorta; H, heart. In contrast to the restricted expression of FLH1 and FLH2, FHL3 displayed a low and ubiquitous expression pattern during mouse development (data not shown). However, in adult tissues, FHL3 expression is more restricted and appears to be inverse of that seen for FHL2, that is, extremely high levels in skeletal muscle, and lower levels in heart (Fig. 2) . As in the case of FHL2, other adult tissues examined did not express detectable levels of FHL3 mRNA.
To determine whether FHL1, FHL2, and FHL3 gene expression is altered during cardiomyopathy, we examined mRNA expression in two mouse models. One of these is a model of hypertrophy, induced by thoracic aortic constriction (TAC). The other is a model of dilated cardiomyopathy, generated by homozygous knockout of a muscle LIM protein (MLP). Northern blot analysis of RNA extracted from hypertrophic or dilated hearts indicated that FHL1 mRNA expression was signi®cantly upregulated in both, relative to control normal hearts. In contrast, expression of either FHL2 or FHL3 mRNAs did not change (Fig. 7A,B) .
These results are consistent with the observation that FHL1 mRNA is increased dramatically in hypertrophic and failing hearts from human patients (Hwang et al., 1997) . In contrast, a recent study demonstrated that FHL1 mRNA levels decreased in patients with dilated cardiomyopathy (Zimmermann et al., 1999) . The different results may be due to the different types and etiologies of cardiomyopathy in these studies.
Material and methods

Genbank and EST database search
We searched Genbank and expressed sequence tag (EST) databases for LIM domain containing proteins using the BLAST search program (Altschul et al., 1997) . Based on our results, we subsequently focused our efforts on the FHL family of proteins that is expressed in striated muscle. Positive EST clones were purchased from Genome Systems Inc.
RNA isolation and Northern blot analysis
To determine the RNA expression pattern of FHL genes in adult mouse tissues, Northern blot analysis was performed using an adult mouse multiple tissue Northern blot (Clontech, #7762-1) containing 2 mg of poly (A) 1 RNA per lane. This blot was probed alternatively with a 425 bp cDNA encoding amino acids 1 to 140 plus 3 bp of 5 H untranslated sequence of FHL1; a 237 bp cDNA sequence encoding amino acids 1±77 plus 6 bp of 5 H untranslated sequence of FHL2; and a 410 bp cDNA sequence encoding amino acids 1±103 of FHL3.
In the transverse aortic constriction (TAC) experiment (described below), total RNA was isolated from left ventricles of both TAC and sham-operated mice using a polytron with RNAzol B (Tel-Test). Total RNA was also isolated in a Fig. 6 . In situ hybridization analyses of FHL2 mRNA during late embryonic development. At E14, FHL2 is strongly expressed in myocardium (A), pituitary gland and tongue (B), umbilical veins and gut (C). Within the heart, expression is very strong in both atrial and ventricular chambers (A,D) with highest level in the ventricular septum (D) and areas adjacent to the atrio-ventricular ring (arrowheads in D). Expression of FHL2 mRNA is also observed in blood vessels, and intestinal smooth muscle (arrowheads in A,C). Symbols are : a, cardiac atria; gt, gut; h, heart; lv, liver; nt, neural tube; pit, pituitary gland; sp, cardiac septum; tn, tongue; uv, umbilical vein; v, ventricle. similar manner from ventricles of wild type and homozygous null MLP mutant mice. Total RNA (10 mg) was electrophoresed on a 1% agarose gel and transferred to a nylon membrane, which was hybridized subsequently with [a-32 P]dATP-labeled FHL1, 2, 3, or GAPDH cDNA probes utilizing QuickHyb solution (Stratagene) as described by the company.
In situ hybridization
Radioactive in situ hybridization of mouse tissues was performed on 7±10 mm paraf®n sections as described (Ruiz-Lozano et al., 1997) . Probes were designed as follows: a 470 bp BamH I-Hind III fragment of FHL1 cDNA (encoding AA 1±140 plus 50 bp of 5 H untranslated region), a 490 bp EcoR I-Pst I fragment of FHL2 cDNA (encoding AA 1±160 plus 10 bp of untranslated region), and a 362 bp Pst I fragment of FHL3 cDNA (encoding AA 165± 285) were each subcloned into pBluescript II KS (Stratagene) to generate templates for sense and antisense 35 S-UTP-or digoxigenin-labeled probes. To evaluate expression patterns of FHL mRNAs during mouse development, both radioactive and non-radioactive RNA in situ hybridization were performed. Non-radioactive in situ hybridization of whole-mount embryos was performed using digoxigeninlabeled synthetic oligo-DNA probes following standard techniques (Faerman and Shani, 1997) .
Whole-mount X-gal staining of FHL1 and FHL2 transgenic embryos
For whole-mount LacZ expression analysis, transgenic embryos were ®xed and stained using standard methods (Ross et al., 1996) . The duration of staining was dependent on color development and ranged from 4 to 12 h at room temperature or 308C. Whole embryos or tissues were analyzed and photographed on a Zeiss SV-6 dissecting microscope with a Nikon C-mount 35mm camera.
Transverse aortic constriction (TAC)
Pressure overload hypertrophy was induced in mice by using a microsurgical technique involving transverse aortic constriction (TAC) as previously described (Rockman et al., 1991) . Sham-operated animals underwent the same operation with no aortic constriction. Transthoracic echocardiography and histological studies were utilized to ensure that ventricular hypertrophic had occurred (data not shown). Fig. 7 . Northern blot analysis of FHL mRNAs in normal and cardiomyopathic hearts. Probes for FHL1, FHL2, and FHL3 RNAs were generated as described in Section 2. Approximately 10 mg total RNA were loaded to each lane. Normalization for loading was performed by hybridization to a probe for GAPDH. (A). RNA from 6-month old MLP knockout mice (lanes 3 and 4) and wildtype littermate controls (lanes 1 and 2) . (B). RNA from hypertrophic left ventricles of TAC mice (T) and sham-operated (S) controls. Note greatly increased expression of FHL1 mRNA in both dilated hearts from MLP mice, and hypertrophic hearts following TAC. In contrast, expressions of FHL2 and FHL3 mRNAs exhibit no change.
